NCT02156388View on ClinicalTrials.gov

Safety and Pharmacokinetic(PK) Study of GW003 to Metastatic Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

31

Participants

Timeline

Start Date

August 31, 2013

Primary Completion Date

February 28, 2015

Study Completion Date

December 31, 2015

Conditions
Chemotherapy-induced NeutropeniaMetastatic Tumors
Interventions
BIOLOGICAL

GW003

freeze-dried powder；single SC injection

Trial Locations (1)

300060

Tianjin Medical University Cancer Institute and Hospital, Tianjin

All Listed Sponsors
lead

Jiangsu T-Mab Biopharma Co.,Ltd

INDUSTRY

NCT02156388 - Safety and Pharmacokinetic(PK) Study of GW003 to Metastatic Tumors | Biotech Hunter | Biotech Hunter